argenx SE header image

argenx SE

ARGX

Equity

ISIN NL0010832176 / Valor 24766616

Euronext - Euronext Brussels (2025-12-19)
EUR 735.80+1.07%

argenx SE
UMushroom community rating:

star star star star star
4.77 3 votes No rating yet
NegativeNeutralPositive

About company

Argenx SE is a biotechnology company that specializes in developing innovative therapies for the treatment of severe autoimmune diseases and cancer. The company leverages its proprietary technology platform to create a portfolio of first-in-class product candidates, which are developed in collaboration with academic partners. Argenx's approach focuses on translating breakthroughs in immunology into effective medicines, aiming to address unmet medical needs. The company's flagship product, efgartigimod, is designed to modulate the immune system and is being explored for multiple autoimmune indications. Argenx is headquartered in the Netherlands and operates globally, with a commitment to advancing its pipeline through rigorous research and development efforts.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

22.7%1Y
107%3Y
197%5Y

Performance

34.0%1Y
39.7%3Y
39.4%5Y

Volatility

Market cap

52713 M

Market cap (USD)

Daily traded volume (Shares)

200,054

Daily traded volume (Shares)

1 day high/low

600 / 594.2

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.77

3 votes
Performance:
starstarstarstarstar
4.54
Innovation:
starstarstarstarstar
5.00
Society:
starstarstarstarstar
4.77
Nature:
starstarstarstarstar
3.62
Laura Sofie Tohver
United Kingdom, 11 Nov 2025
star star star star star
Emerging technology and nice returns
Viktor Stockel
Switzerland, 30 Oct 2025
star star star star star
Argenx SE is a commercial-stage, global biopharmaceutical company focused on immunology, particularly therapies for severe autoimmune diseases.
Claudia Stadelmann
Switzerland, 05 Mar 2025
star star star star star
Geheimtipp belgisches Biotech mit spannender Pipeline

EQUITIES OF THE SAME SECTOR

Syzygy AG
Syzygy AG Syzygy AG Valor: 1127753
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.27%EUR 1.55
Alibaba Group Holding Ltd
Alibaba Group Holding Ltd Alibaba Group Holding Ltd Valor: 24409862
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.68%USD 149.79
Digital Turbine Inc
Digital Turbine Inc Digital Turbine Inc Valor: 25638656
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.84%USD 5.26
Five9 Inc
Five9 Inc Five9 Inc Valor: 23875956
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.24%USD 20.54
Natera Inc
Natera Inc Natera Inc Valor: 28447012
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.21%USD 231.96
Grand Canyon Education Inc
Grand Canyon Education Inc Grand Canyon Education Inc Valor: 4243864
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.66%USD 165.93
Grifols, SA
Grifols, SA Grifols, SA Valor: 30689493
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.53%EUR 10.96
REN - Redes Energeticas Nacionais SGPS, SA
REN - Redes Energeticas Nacionais SGPS, SA REN - Redes Energeticas Nacionais SGPS, SA Valor: 3219586
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.87%EUR 3.21
LPKF Laser & Electronics SE
LPKF Laser & Electronics SE LPKF Laser & Electronics SE Valor: 967495
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.90%EUR 5.35
NanoRepro AG
NanoRepro AG NanoRepro AG Valor: 4691951
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.32%EUR 1.56